Together, our data strongly argue that therapeutic strategies disrupting HIF-1α/HIF-1β dimerization would be able to switch the tumor microenvironment from immunosuppressive to immunopermissive for the infiltration of NK and CD8+ effector T cells. This evidence concerns the gene HIF1A and neoplasm.